Ibrance was the first CDK4/6 inhibitor to reach the U.S. market, in February 2015, and eleven years later it still has no generic competitor you can actually buy. What it does have is an unusual pricing quirk: the same drug, at the same strength, costs $3,360.73 more per cycle in tablet form than in capsule form. And Pfizer has told FDA it is retiring the cheaper one.
The other thing that shapes the bill is the schedule. Ibrance is taken once daily for 21 straight days and then not at all for 7, so a “month” of this drug is 21 units, not 28 or 30. That makes the per-cycle number the one to hold in your head. Every figure below was researched on September 3, 2026.
What Does Ibrance Cost Without Insurance?
Dosing comes from the FDA-approved prescribing information, effective July 6, 2026: 125 mg once daily for 21 consecutive days followed by 7 days off, comprising a 28-day cycle. Cash retail comes from the Drugs.com price guide. The Medicare rows come from the CMS Part D Spending by Drug file for 2024 and from the CMS fact sheet on negotiated prices for 2027, published November 2025. There is no NADAC acquisition benchmark for palbociclib.
| CDK4/6 inhibitor purchase | Low | Average | High |
|---|---|---|---|
| Ibrance capsule, per unit (75, 100 or 125 mg) | $629.03 | $629.03 | $629.03 |
| Ibrance tablet, per unit (75, 100 or 125 mg) | $789.07 | $789.07 | $789.07 |
| Ibrance capsule, 21-unit cycle | $13,209.65 | $13,209.65 | $13,209.65 |
| Ibrance tablet, 21-unit cycle | $16,570.38 | $16,570.38 | $16,570.38 |
| One Ibrance cycle across all sources | $13,209.65 | $15,629.01 | $16,570.38 |
| Medicare Part D average paid per Ibrance claim, 2024 | $15,471.10 | $15,471.10 | $15,471.10 |
| CMS-published Ibrance list price, 30-day supply, 2024 | $15,741 | $15,741 | $15,741 |
| Medicare negotiated Ibrance price, effective Jan 1 2027 | $7,871 | $7,871 | $7,871 |
| Verzenio (abemaciclib), average per Part D claim, 2024 | $14,690.86 | $14,690.86 | $14,690.86 |
| Kisqali (ribociclib), average per Part D claim, 2024 | $14,749.40 | $14,749.40 | $14,749.40 |
| Pfizer co-pay card price, commercial insurance only | $0 | $0 | $0 |
The middle figure of $15,629.01 on the combined row is the CMS Part D weighted average of $744.23 per dosage unit multiplied by the 21 units in a cycle. It lands within about one percent of the $15,471.10 CMS separately reports as the average amount actually paid per Ibrance prescription claim, which is a strong sign both numbers are describing the same real-world 21-unit fill.
The three CDK4/6 inhibitors price remarkably close to each other on a per-claim basis in Medicare: $15,471 for Ibrance, $14,749 for Kisqali and $14,691 for Verzenio. Note that Verzenio is dosed twice daily and continuously rather than on a 21-and-7 schedule, so a claim covers a different amount of drug. Treat that row as a rough market comparison, not a like-for-like swap, and remember that these are not interchangeable products.
What Drives the Price
No marketed generic, eleven years in. FDA’s Drugs@FDA database shows ten palbociclib applications from Sun, Dr. Reddy’s, Eugia, Aizant, MSN, Cipla, Natco, Chia Tai Tianqing, Biocon and a second Dr. Reddy’s filing, every one of them stuck at tentative approval. One application, from Zydus Lifesciences, was approved June 5, 2024 and is now listed as discontinued. Drugs.com’s generic availability page, updated July 9, 2026, states more simply that no generic version has been approved. Whichever framing you prefer, nothing is on the shelf.
The cheaper form is being retired. On April 22, 2026 Pfizer posted a discontinuation notice to FDA covering the Ibrance capsule presentation, stating plainly that it is discontinuing manufacture of the capsule and that the corresponding tablet strengths will continue to be manufactured. The current label, effective July 6, 2026, already describes the recommended dose as a 125 mg tablet. For a cash payer, moving from capsule to tablet is a $3,360.73 increase per cycle, or just over $40,000 a year.
The 21-and-7 schedule confuses quotes. A pharmacy quoting you a “monthly” price may be quoting 21 units, which is what the label calls for, or normalizing to 30 days, which is what CMS does when it publishes a list price. That is part of why the CMS 2024 list price of $15,741 for a 30-day supply and the Drugs.com tablet cycle price of $16,570.38 do not match exactly. Always ask how many capsules or tablets the quote covers.
Price is flat across strengths. All three strengths, 75 mg, 100 mg and 125 mg, cost the same per unit. A dose reduction for tolerability does not reduce your bill at all.
The Medicare price is about to be halved, but not for you. CMS negotiated a maximum fair price of $7,871 per 30-day supply, effective January 1, 2027, against the published 2024 list price of $15,741. That is a 50 percent cut and it is one of the largest oncology reductions in the program’s second cycle. It applies to Medicare, not to cash payers.
Cash Price vs. Insurance
If you have commercial insurance, the gap between what you pay and what a cash payer pays is close to total. Pfizer Oncology Together states that eligible commercially insured patients may pay as little as $0 per month for a Pfizer oncology oral medicine, with savings of up to $10,600 per product per year, and that there are no income requirements for the co-pay programs. Patients enrolled in Medicare, Medicaid, TRICARE, VA health care, a state prescription drug assistance program or the Government Health Insurance Plan in Puerto Rico are excluded.
If you are uninsured, the co-pay card is not available to you and the route is the Pfizer Patient Assistance Program, which Pfizer describes as providing Pfizer oncology medicines free to eligible patients who cannot afford them. That program runs in the opposite direction from the card: uninsured and government-insured patients may qualify, and commercially insured patients are explicitly not eligible regardless of plan. Pfizer does not publish an income ceiling on the page, so ask for the current threshold when you apply.
Practically, that means almost nobody should be paying the $13,210 to $16,570 cash number for long. It is the price you pay in the gap between diagnosis and an approved assistance application, and shortening that gap is the whole game.
How to Pay Less
Start the patient assistance application the day it is prescribed. The co-pay card is closed to uninsured patients, so the program you want is the Pfizer Patient Assistance Program through Pfizer Oncology Together. Approvals are not instant, and every week of delay at this price point is roughly $4,000.
Ask for capsules while they still exist. Until Pfizer’s capsule inventory runs out, the capsule cycle is $3,360.73 cheaper than the tablet cycle at cash retail. Whether a switch is appropriate is a clinical question for your oncologist, but it is worth knowing the number exists before the option disappears.
Ask about a 340B pharmacy. Federally qualified health centers and disproportionate-share hospitals buy at deeply discounted 340B prices and many pass that through to uninsured patients on a sliding scale. Our guide to free and sliding-scale clinics covers how to find one and what to ask.
Use charity care and negotiation for everything around the drug. Metastatic breast cancer care is not just the pill. Scans, labs, infusions and office visits all generate separate bills, and those are negotiable in a way a pharmacy counter is not. Start with hospital charity care, then work the statement with how to negotiate medical bills and a request for an itemized bill.
Quote the $7,871 Medicare number. CMS has published, in a public document, what this drug is worth in a negotiated transaction. That is a concrete anchor for a hardship conversation with a specialty pharmacy or the manufacturer. Our negotiation script tool gives you the wording, and the fair price checker helps you benchmark the rest of the care.
Price the endocrine therapy separately. Ibrance is given alongside hormonal therapy, and that piece can be very cheap. See our guides to letrozole costs and tamoxifen costs so you are not overpaying for the inexpensive half of the regimen.
The Bottom Line
Ibrance runs $13,209.65 per cycle as a capsule and $16,570.38 as a tablet at cash retail in September 2026, with CMS Part D data landing in between at about $15,629 for the same 21 units. Medicare will pay $7,871 for a 30-day supply starting in 2027. There is no generic and nothing close to a launch.
Two things to watch. The capsule discontinuation means the cash price on this page is heading up, not down, for anyone still using it. And with ten tentatively approved generics waiting, the day one of them converts to a full approval and ships, this article needs a rewrite rather than a refresh. For related screening and oncology costs, see our guides to mammogram costs, genetic testing costs and chemotherapy costs.